Japan Next Generation Sequencing Market Insights Forecasts to 2032

• The Japan Next Generation Sequencing Market Size was valued at USD 296.45 Million in 2022.
• The Market Size is growing at a CAGR of 23.5% from 2022 to 2032.
• The Japan Next Generation Sequencing Market Size is expected to reach USD 2475.55 Million by 2032.

The Japan Next Generation Sequencing Market Size is expected to reach USD 2475.55 Million by 2032, at a CAGR of 23.5% during the forecast period 2022 to 2032.

Market Overview

The decreasing cost of genetic sequencing and technological advancements in cloud computing and data integration are major factors contributing to the market growth. Moreover, increasing spending on cancer treatment and wide utilization of NGS in cancer diagnosis and treatment is expected to boost the market growth. The rising prevalence of cancer across the country is anticipated to support the market expansion over the forecast period. The cost of genetic sequencing has dropped significantly, which is expected to increase demand for genome sequencing. Major market participants are introducing novel solutions to the market, which is lowering the cost of sequencing. Japan's next-generation sequencing market is defined by a high degree of innovation, with novel technologies and instruments being developed and introduced frequently. The development of the next-generation sequencing (NGS) market in Japan is being fueled by several factors that are combined to accelerate its rapid growth.

Report Coverage

This research report categorizes the market for Japan next generation sequencing market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan next generation sequencing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan next generation sequencing market.

Driving Factors

Continuous advancements in NGS platforms, such as the incorporation of technologies like single-cell sequencing and long-read sequencing, contribute to improved accuracy, throughput, and cost-effectiveness. By widening the scope and capabilities of genomic analysis, this technological advancement drives the market over the forecast period. Additionally, in Japan, supportive government initiatives and a favorable regulatory environment are critical drivers of the NGS market during the forecast period. Ongoing efforts to streamline approval processes for NGS-based diagnostics and therapies foster an environment that promotes genomic research, development, and deployment in healthcare. Numerous driving factors expand the applications of NGS in healthcare, including diagnostics, prognostics, and treatment selection. Continued research into the genomic basis of diseases, as well as the development of validated NGS-based diagnostic assays, have the potential to transform clinical practices by providing more precise and personalized healthcare solutions.

Restraining Factors

While next-generation sequencing provides unprecedented amounts of genomic information, interpreting complex data sets remains a significant challenge. Identifying relevant genetic variations and translating this information into actionable insights for clinical decision-making requires advanced bioinformatics tools and expertise. Bridging the gap between raw data and meaningful results is a never-ending challenge.

Market Segment

• In 2022, the targeted sequencing & resequencing segment accounted for the largest revenue share over the forecast period.

Based on the technology, Japan next generation sequencing market is segmented into whole genome sequencing, whole exome sequencing, targeted sequencing & resequencing, and others. Among these, the targeted sequencing & resequencing segment has the largest revenue share over the forecast period. This segmental dominance can be attributed to the numerous benefits provided by this technology for next-generation sequencing. This is a low-cost technique that provides physicians with actionable and clear information.

• In 2022, the oncology segment accounted for the largest revenue share over the forecast period.

Based on application, Japan next generation sequencing market is segmented into oncology, HLA typing/immune system monitoring, clinical investigation, epidemiology & drug development, reproductive health, metagenomics, agrigenomics & forensics, consumer genomics, and others. Among these, the oncology segment has the largest revenue share over the forecast period. This segment dominance can be attributed to the widespread use of next-generation sequencing (NGS) in oncology, where gene mutations are sequenced to develop new cancer diagnostic and treatment methods. NGS in oncology has also aided in a better understanding of various tumor growth cell signaling pathways, providing oncologists with insights for better diagnosis and management of various cancers. With the decrease in the cost of whole genome sequencing, the use of NGS in oncology will increase significantly during the forecast period.

• In 2022, the academic research segment accounted for the largest revenue share over the forecast period.

Based on end use, the Japan next generation sequencing market is segmented into clinical research, academic research, pharma & biotech entities, hospitals & clinics, and other users. Among these, the academic research segment has the largest revenue share over the forecast period. The segmental growth can be attributed to the availability of various institutes providing on-site bioinformatics courses and training programs that improve knowledge about various sequencing data analysis solutions, which are expected to drive the segmental growth during the forecast period.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within Japan next generation sequencing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Illumina, Inc
• QIAGEN
• Thermo Fisher Scientific, Inc
• BGI
• Pacific Biosciences
• Bio Rad Laboratories
• Oxford Nanopore Technologies, Inc
• Myriad Genetics. Inc.
• Agilent Technologies, Inc
• Eurofins Scientific
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2023, Astride, a major NGS service distributor in Japan, collaborated with Basepair to distribute its visualization platform to the Japanese market.

• In April 2023, Agilent Technologies Inc. introduced a next-generation sequencing (NGS) assay for comprehensive genomic profiling (CGP) to advance precision oncology.

• In March 2023, Illumina, Inc. introduced a product based on its novel Illumina Complete Long Read technology that combines short- and long-read sequencing on a single instrument.

Market Segment

This study forecasts revenue at regional, and country levels from 2021 to 2032. Spherical Insights has segmented Japan next generation sequencing market based on the below-mentioned segments:

Japan Next Generation Sequencing Market, By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
• Others

Japan Next Generation Sequencing Market, By Application

• Oncology
• HLA Typing/Immune System Monitoring
• Clinical Investigation
• Epidemiology & Drug Development
• Reproductive Health
• Metagenomics
• Agrigenomics & Forensics
• Consumer Genomics
• Others

Japan Next Generation Sequencing Market, By End Use

• Clinical Research
• Academic Research
• Pharma & Biotech Entities
• Hospitals & Clinics
• Other Users